Tumor/Biomarker-Specific Combination Strategies with the RAF/MEK Clamp VS-6766
Time: 4:30 pm
day: Day One Track H
Details:
- VS-6766 blocks the RAS pathway through a novel RAF/MEK clamp mechanism
- Rationale for ongoing combination trials with VS-6766 with defactinib or everolimus
- Novel VS-6766 combinations for tumor/biomarkerspecific patient populations
